Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis. Issue 3 (24th March 2022)

• Record Type: Journal Article
• Authors: Decroo, Tom; Aung, Kya Jai Maug; Hossain, Mohamed Anwar; Gumusboga, Mourad; Ortuno-Gutierrez, Nimer; De Jong, Bouke Catherine; Van Deun, Armand
• Is Part Of: European respiratory journal. Volume 59:Issue 3(2022)
• Publication Date: 2022-03-24
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.02124-2021
• Languages: English
• ISSNs: 0903-1936

Abstract

In Bangladesh, a standardised short treatment regimen (STR) was highly effective in patients diagnosed with rifampicin-resistant tuberculosis (RR-TB), without proof of initial resistance to fluoroquinolone, and no prior treatment for RR-TB [1]. The STR relied on a fluoroquinolone, either gatifloxacin, levofloxacin or moxifloxacin, as core drug, with gatifloxacin being most effective in assuring relapse-free cure [2]. A second-line injectable was used during at least the first four months to prevent the selection of fluoroquinolone-resistant (sub)populations [3]. Other drugs served as companion drugs. In the original short treatment regimen for rifampicin-resistant tuberculosis, bedaquiline proved an adequate core drug for fluoroquinolone resistance, ensuring early conversion and relapse-free cure. Use of linezolid did not have the same early effect. https://bit.ly/3gWuf9z